ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

ClinicalTrials.gov ID: NCT02807636

Public ClinicalTrials.gov record NCT02807636. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 12, 2026, 8:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Chemotherapy in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Study identification

NCT ID
NCT02807636
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
1,213 participants

Conditions and interventions

Interventions

  • Atezolizumab Drug
  • Carboplatin Drug
  • Cisplatin Drug
  • Gemcitabine Drug
  • Placebo Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 29, 2016
Primary completion
Aug 30, 2022
Completion
Feb 11, 2024
Last update posted
Feb 23, 2025

2016 – 2024

United States locations

U.S. sites
18
U.S. states
14
U.S. cities
18
Facility City State ZIP Site status
Highlands Oncology Group Rogers Arkansas 72758
Coastal Integrative Cancer Care San Luis Obispo California 93401
Yale School of Medicine New Haven Connecticut 06520-8032
Norwalk Hospital Norwalk Connecticut 06856
Christina Care Institutional Review Board Newark Delaware 19713
Florida Cancer Specialists Fort Myers Florida 33916
UF Health Cancer Center at Orlando Health Orlando Florida 32824
Florida Cancer Specialists (St. Petersburg ? St. Anthony?s Professional Building) St. Petersburg Florida 33705
Moffitt Cancer Center Tampa Florida 33612
Parkview Research Center Fort Wayne Indiana 46845
Norton Cancer Institute Louisville Kentucky 40402
East Jefferson Hematology Oncology Metairie Louisiana 70006
Park Nicollet Clin-Cancer Ctr Saint Louis Park Minnesota 55426
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89148
Mount Sinai School of Medicine - Tisch Cancer Institute New York New York 10029
University of North Carolina, Lineberger Cancer Ctr Chapel Hill North Carolina 27599
Bon Secours - St. Francis Hospital Greenville South Carolina 29607
Sarah Cannon Research Institute / Tennessee Oncology Nashville Tennessee 37203

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 186 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02807636, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 23, 2025 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02807636 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →